Edoxaban Zentiva
Direct Oral Anticoagulant (DOAC) — Factor Xa Inhibitor
Edoxaban Zentiva is a direct oral anticoagulant (DOAC) that works by selectively inhibiting Factor Xa in the blood coagulation cascade. It is prescribed to prevent stroke and systemic embolism in adults with non-valvular atrial fibrillation, and to treat and prevent recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE). The 15 mg tablet is the reduced-dose formulation used for patients who require dose adjustment based on specific clinical factors.
Quick Facts
Key Takeaways
- Edoxaban Zentiva 15 mg is the reduced-dose formulation of edoxaban, a direct Factor Xa inhibitor used to prevent stroke in atrial fibrillation and treat blood clots (DVT/PE).
- It is taken once daily by mouth, with or without food, and does not require routine blood monitoring like warfarin.
- The most important risk is bleeding; seek immediate medical attention for signs of unusual or excessive bleeding.
- Never stop taking Edoxaban Zentiva without consulting your doctor, as abrupt discontinuation increases the risk of blood clots and stroke.
- Inform all healthcare providers (including dentists) that you are taking this medication before any procedure or surgery.
What Is Edoxaban Zentiva and What Is It Used For?
Edoxaban Zentiva contains the active substance edoxaban tosilate hydrate. It is classified as a direct oral anticoagulant (DOAC), also known as a novel oral anticoagulant (NOAC). Unlike older anticoagulants such as warfarin, edoxaban works by directly and selectively inhibiting a single target in the coagulation cascade — Factor Xa — without requiring the cofactor antithrombin III. This mechanism provides a more predictable anticoagulant effect with fewer drug and food interactions.
The medication is approved by the European Medicines Agency (EMA) and other international regulatory agencies for two primary indications. The first is the prevention of stroke and systemic embolism in adult patients who have non-valvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, or prior stroke or transient ischemic attack. Atrial fibrillation causes the upper chambers of the heart to beat irregularly, which can allow blood to pool and form clots that may travel to the brain, causing a stroke.
The second approved indication is the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and the prevention of recurrent DVT and PE in adults. Deep vein thrombosis occurs when a blood clot forms in a deep vein, usually in the leg, while pulmonary embolism is a potentially life-threatening condition where a blood clot breaks free and travels to the lungs. For DVT/PE treatment, edoxaban is initiated after at least 5 days of initial parenteral anticoagulation therapy (such as heparin or low molecular weight heparin).
The 15 mg tablet is the reduced-dose formulation of edoxaban. It is typically prescribed for patients who meet specific criteria for dose reduction, such as those with moderate renal impairment (creatinine clearance 15–50 mL/min), low body weight (60 kg or less), or those who are concomitantly using certain P-glycoprotein (P-gp) inhibitors such as cyclosporine, dronedarone, erythromycin, or ketoconazole. Appropriate dose selection is critical because the ENGAGE AF-TIMI 48 trial demonstrated that a higher dose of edoxaban (60 mg) was more effective than the lower dose in patients without these specific risk factors.
How Edoxaban Works in Your Body
After oral administration, edoxaban is rapidly absorbed from the gastrointestinal tract, reaching peak plasma concentrations within 1 to 2 hours. The oral bioavailability is approximately 62%. Once in the bloodstream, edoxaban selectively and reversibly binds to the active site of Factor Xa, blocking its ability to convert prothrombin to thrombin. Since thrombin is essential for converting fibrinogen to fibrin — the protein mesh that forms the structural basis of blood clots — inhibiting Factor Xa effectively reduces the body's ability to form new blood clots.
Edoxaban has a half-life of approximately 10 to 14 hours, which supports once-daily dosing. It is metabolized primarily by hydrolysis and through CYP3A4 and P-glycoprotein transport. Approximately one-third of the drug is eliminated renally, with the remainder excreted through feces. This dual elimination pathway means that renal impairment significantly affects drug levels, which is why dose reduction to 15 mg is recommended for patients with moderate kidney dysfunction.
What Should You Know Before Taking Edoxaban Zentiva?
Contraindications
Edoxaban Zentiva must not be used in certain situations due to the risk of serious, potentially life-threatening complications. Your doctor will assess your individual risk profile before prescribing this medication. The following are absolute contraindications:
- Active clinically significant bleeding: This includes any ongoing bleeding from the gastrointestinal tract, urinary tract, respiratory tract, or any other site that requires medical intervention.
- Hepatic disease associated with coagulopathy: Severe liver disease that impairs the body's ability to produce clotting factors significantly increases bleeding risk.
- Lesions or conditions at significant risk of major bleeding: This includes current or recent gastrointestinal ulceration, known esophageal varices, arteriovenous malformations, vascular aneurysms, or major intraspinal or intracerebral vascular abnormalities.
- Uncontrolled severe hypertension: Persistently elevated blood pressure that is not adequately managed with treatment.
- Concomitant treatment with other anticoagulants: Such as unfractionated heparin, low molecular weight heparins, warfarin, or other direct oral anticoagulants, except during transitioning between therapies.
- Prosthetic heart valves requiring anticoagulation: Edoxaban has not been studied in patients with mechanical heart valves and should not be used in this population.
- Known hypersensitivity: Allergy to edoxaban or any of the excipients in the formulation.
Warnings and Precautions
Special care is needed when using Edoxaban Zentiva in certain patient populations and clinical situations. Discuss all of the following with your doctor before starting treatment:
As with all anticoagulants, Edoxaban Zentiva increases the risk of bleeding. Bleeding can occur at any site and may be severe or fatal. Signs of bleeding include unexplained bruising, blood in urine (pink or brown), black or bloody stools, coughing up blood, prolonged nosebleeds, bleeding gums, unusually heavy menstrual bleeding, or sudden severe headache. Seek emergency medical care immediately if any of these occur.
Renal function: Kidney function directly affects edoxaban levels in the blood. Your doctor should assess your kidney function (creatinine clearance) before starting treatment and periodically during therapy. Patients with severe renal impairment (CrCl < 15 mL/min) or those on dialysis should not use edoxaban. Additionally, the ENGAGE AF-TIMI 48 trial suggested that edoxaban may be less effective than warfarin in patients with a creatinine clearance above 95 mL/min for stroke prevention in atrial fibrillation.
Hepatic impairment: Patients with severe hepatic impairment (Child-Pugh C) should not use edoxaban. Those with mild to moderate liver impairment (Child-Pugh A or B) should be monitored carefully, though no dose adjustment is generally required if coagulation parameters are not affected.
Spinal/epidural procedures: Patients receiving neuraxial anesthesia or undergoing spinal puncture while on anticoagulants are at risk of developing spinal or epidural hematomas, which can result in long-term or permanent paralysis. The risk is increased by the use of indwelling epidural catheters, concomitant use of other drugs that affect hemostasis, traumatic or repeated puncture, or a history of spinal deformity or surgery.
Surgical and invasive procedures: If surgery or an invasive procedure is required, edoxaban should be stopped at least 24 hours before the procedure. If the procedure carries a high bleeding risk, stopping at least 48 hours beforehand may be advisable. Edoxaban can be restarted as soon as adequate hemostasis has been established.
Pregnancy and Breastfeeding
Edoxaban Zentiva is not recommended during pregnancy. There are no adequate and well-controlled studies in pregnant women. Animal studies have shown reproductive toxicity. The potential risk to the fetus is unknown, and anticoagulant therapy during pregnancy carries inherent risks of bleeding. Women of childbearing potential should use effective contraception during treatment.
It is not known whether edoxaban is excreted in human breast milk. Animal studies have shown excretion of edoxaban in milk. Therefore, breastfeeding is not recommended during treatment with Edoxaban Zentiva. A decision must be made whether to discontinue breastfeeding or to discontinue therapy, taking into account the benefit of breastfeeding for the child and the benefit of therapy for the mother.
How Does Edoxaban Zentiva Interact with Other Drugs?
Drug interactions with edoxaban are primarily mediated through P-glycoprotein (P-gp) transport and, to a lesser extent, CYP3A4 metabolism. Understanding these interactions is essential for safe use, as they can either increase bleeding risk or reduce the drug's effectiveness. Always inform your doctor and pharmacist about all medications you are taking, including prescription drugs, over-the-counter medicines, and herbal supplements.
Major Interactions
The following interactions are considered clinically significant and may require dose adjustment, additional monitoring, or avoidance of combination therapy:
| Drug / Drug Class | Effect on Edoxaban | Clinical Recommendation |
|---|---|---|
| Cyclosporine | Increases edoxaban levels (P-gp inhibition) | Reduce edoxaban dose to 15 mg daily |
| Dronedarone | Increases edoxaban levels (P-gp inhibition) | Reduce edoxaban dose to 15 mg daily |
| Erythromycin | Increases edoxaban levels (P-gp inhibition) | Reduce edoxaban dose to 15 mg daily |
| Ketoconazole | Increases edoxaban levels (P-gp inhibition) | Reduce edoxaban dose to 15 mg daily |
| Warfarin / other anticoagulants | Additive anticoagulant effect | Concomitant use contraindicated (except during switching) |
| Rifampicin | Reduces edoxaban levels (P-gp induction) | Avoid concomitant use; may reduce anticoagulant efficacy |
| Phenytoin / Carbamazepine | Reduces edoxaban levels (P-gp induction) | Avoid concomitant use; may reduce anticoagulant efficacy |
Moderate Interactions
These interactions may increase bleeding risk and require careful clinical monitoring:
- Aspirin (acetylsalicylic acid): Low-dose aspirin (up to 100 mg) can be co-administered with caution for specific indications (e.g., acute coronary syndrome), but increases bleeding risk. Higher doses should be avoided.
- NSAIDs (ibuprofen, naproxen, diclofenac): Non-steroidal anti-inflammatory drugs affect platelet function and increase gastrointestinal bleeding risk. Use with caution and for the shortest duration possible.
- Antiplatelet agents (clopidogrel, ticagrelor, prasugrel): Dual or triple antithrombotic therapy significantly increases bleeding risk. Use only when clinically necessary and with close monitoring.
- SSRIs and SNRIs (sertraline, fluoxetine, venlafaxine): These antidepressants impair platelet aggregation and may increase bleeding risk when combined with anticoagulants.
- Verapamil: A P-gp inhibitor that modestly increases edoxaban exposure. No dose adjustment is typically needed, but clinical monitoring is recommended.
Food and Herbal Interactions
Unlike warfarin, edoxaban does not have clinically significant interactions with dietary vitamin K, meaning patients do not need to restrict their intake of green leafy vegetables. However, St. John's Wort (Hypericum perforatum) is a potent P-gp inducer and should be avoided, as it may reduce edoxaban's anticoagulant effectiveness. Grapefruit juice has minimal effect on edoxaban pharmacokinetics and does not require avoidance.
What Is the Correct Dosage of Edoxaban Zentiva?
Dosing of edoxaban requires careful consideration of the patient's clinical characteristics. The 15 mg tablet is the reduced-dose formulation and should only be used when specific dose-reduction criteria are met. Your doctor will determine the appropriate dose based on your individual risk factors.
Adults — Atrial Fibrillation (Stroke Prevention)
Standard dose: 60 mg once daily
The recommended dose for most adults with non-valvular atrial fibrillation is 60 mg once daily. Treatment should be continued long-term unless the benefit no longer outweighs the risk.
Reduced dose: 30 mg once daily (or 15 mg in specific cases)
The dose is reduced to 30 mg once daily for patients with one or more of the following: creatinine clearance 15–50 mL/min, body weight ≤60 kg, or concomitant use of P-gp inhibitors (cyclosporine, dronedarone, erythromycin, or ketoconazole). The 15 mg dose may be used when multiple dose-reduction factors are present or as clinically indicated.
Adults — DVT/PE Treatment and Prevention
Standard dose: 60 mg once daily
For the treatment of DVT and PE, edoxaban 60 mg once daily is started following at least 5 days of initial parenteral anticoagulation therapy (e.g., enoxaparin, unfractionated heparin). Treatment duration depends on the clinical situation: typically 3 months for provoked DVT/PE, and longer (up to indefinite) for unprovoked or recurrent events.
Reduced dose: 30 mg once daily (or 15 mg in specific cases)
The same dose-reduction criteria apply: CrCl 15–50 mL/min, body weight ≤60 kg, or concomitant P-gp inhibitor use. The 15 mg dose may apply in combined dose-reduction scenarios.
Dosage Table by Patient Group
| Patient Group | Standard Dose | Reduced Dose | Notes |
|---|---|---|---|
| Adults (NVAF) | 60 mg once daily | 30 mg once daily | Long-term use; assess CrCl before starting |
| Adults (DVT/PE) | 60 mg once daily | 30 mg once daily | After ≥5 days parenteral anticoagulation |
| CrCl 15–50 mL/min | — | 30 mg (or 15 mg) | Mandatory dose reduction |
| Body weight ≤60 kg | — | 30 mg (or 15 mg) | Mandatory dose reduction |
| P-gp inhibitor use | — | 30 mg (or 15 mg) | Cyclosporine, dronedarone, erythromycin, ketoconazole |
| Elderly (≥75 years) | 60 mg once daily | 30 mg if criteria met | No age-based adjustment alone; assess CrCl |
| CrCl <15 mL/min or dialysis | — | — | Not recommended; insufficient data |
Children
The safety and efficacy of Edoxaban Zentiva have not been established in children and adolescents under 18 years of age. There are currently no data available to support dosing recommendations in the pediatric population. Edoxaban should not be used in patients under 18 years.
Elderly
No dose adjustment is required based on age alone. However, elderly patients are more likely to have reduced renal function, lower body weight, and comorbidities that may independently warrant dose reduction. Renal function should be assessed before starting therapy and monitored periodically. The ENGAGE AF-TIMI 48 trial included a significant proportion of patients over 75, and edoxaban demonstrated a consistent safety and efficacy profile in this subgroup.
Missed Dose
If you forget to take a dose of Edoxaban Zentiva, take it as soon as you remember on the same day. If you cannot remember to take the dose until the next day, skip the missed dose and take your next dose at the usual scheduled time. Do not take a double dose to compensate for the forgotten dose. Taking two doses on the same day increases bleeding risk. If you are unsure about what to do, contact your doctor or pharmacist.
Overdose
Taking more edoxaban than prescribed increases the risk of bleeding. There is no specific approved antidote for edoxaban, although andexanet alfa (a recombinant Factor Xa protein) has been studied and approved in some countries as a reversal agent for Factor Xa inhibitors. In the event of overdose, contact your local poison control center or seek emergency medical attention immediately. Treatment is supportive and may include oral activated charcoal if taken within a few hours of ingestion, and consideration of four-factor prothrombin complex concentrate (4F-PCC) in cases of severe bleeding. Hemodialysis does not significantly remove edoxaban from the circulation.
What Are the Side Effects of Edoxaban Zentiva?
Like all medicines, Edoxaban Zentiva can cause side effects, although not everybody gets them. The most important and common side effect is bleeding, which is expected given the drug's mechanism of action as an anticoagulant. The frequency classifications below are based on clinical trial data from the ENGAGE AF-TIMI 48 study (21,105 patients) and the Hokusai-VTE study (8,292 patients), as well as post-marketing surveillance data.
Common
Affects 1 to 10 in every 100 patients
- Bleeding from the nose (epistaxis)
- Bleeding from the gastrointestinal tract (stomach, intestines)
- Bleeding from the skin and soft tissue (bruising, ecchymosis)
- Bleeding from the gums (gingival hemorrhage)
- Blood in the urine (hematuria)
- Vaginal bleeding (menorrhagia, metrorrhagia)
- Skin rash
- Itching (pruritus)
- Abnormal liver function tests (elevated transaminases)
- Anemia (low red blood cell count)
Uncommon
Affects 1 to 10 in every 1,000 patients
- Intracranial hemorrhage (bleeding in or around the brain)
- Bleeding from surgical wounds
- Hemoptysis (coughing up blood)
- Rectal bleeding
- Bleeding from the conjunctiva (eye)
- Thrombocytopenia (low platelet count)
- Urticaria (hives)
- Elevated bilirubin
- Elevated alkaline phosphatase
Rare
Affects fewer than 1 in every 1,000 patients
- Allergic or anaphylactic reactions
- Subarachnoid hemorrhage
- Pericardial hemorrhage (bleeding around the heart)
- Retroperitoneal hemorrhage
- Intramuscular bleeding (with compartment syndrome)
- Intraocular bleeding
- Adrenal gland hemorrhage
Contact emergency services or go to the nearest emergency department immediately if you experience: sudden severe headache, confusion, or difficulty speaking (possible intracranial bleeding); vomiting blood or material that looks like coffee grounds; black, tarry stools; severe abdominal pain; heavy or uncontrollable bleeding from any site; or signs of severe allergic reaction (swelling of face, lips, tongue, or throat, difficulty breathing).
In the ENGAGE AF-TIMI 48 trial, edoxaban demonstrated significantly lower rates of major bleeding compared to warfarin (2.75% per year vs. 3.43% per year, hazard ratio 0.80). The rate of intracranial hemorrhage was particularly favorable, with edoxaban showing approximately a 50% reduction compared to warfarin. However, gastrointestinal bleeding was slightly more common with edoxaban 60 mg compared to warfarin, though this difference was not seen with the reduced-dose regimen.
If you experience any side effects, including any not listed above, talk to your doctor, pharmacist, or nurse. You can also report side effects directly to your national pharmacovigilance authority. By reporting side effects, you can help provide more information on the safety of this medicine.
How Should You Store Edoxaban Zentiva?
Proper storage of medications ensures they remain effective and safe throughout their shelf life. Edoxaban Zentiva film-coated tablets should be stored at a temperature not exceeding 30°C (86°F). No special temperature storage conditions are required beyond this upper limit, meaning the tablets can be kept at normal room temperature in most climates.
Keep the tablets in the original blister packaging to protect them from moisture. The blister packs are designed to maintain the integrity of the medication until the time of use. Do not transfer the tablets to a different container, as this may expose them to environmental conditions that could degrade the active substance.
Keep this medicine out of the sight and reach of children. Children may be particularly vulnerable to the effects of anticoagulant medications, and accidental ingestion could cause serious bleeding complications. Store the medication in a secure location, ideally in a locked medicine cabinet.
Do not use Edoxaban Zentiva after the expiry date printed on the carton and blister pack. The expiry date refers to the last day of that month. Do not dispose of medications via wastewater or household waste. Ask your pharmacist how to dispose of medicines you no longer use. These measures help to protect the environment and prevent accidental exposure.
What Does Edoxaban Zentiva Contain?
Understanding the composition of your medication can be important, particularly if you have known allergies or intolerances to specific pharmaceutical ingredients.
Active Substance
Each film-coated tablet contains edoxaban 15 mg (as edoxaban tosilate hydrate). Edoxaban tosilate hydrate is the salt form used in the pharmaceutical formulation because it offers favorable stability and bioavailability characteristics. The tosilate salt facilitates consistent dissolution and absorption in the gastrointestinal tract.
Tablet Core Excipients
The tablet core contains the following inactive ingredients:
- Mannitol (E421): A sugar alcohol used as a diluent and bulking agent.
- Pregelatinised starch: Serves as a binder and disintegrant, helping the tablet dissolve in the stomach.
- Crospovidone: A super-disintegrant that promotes rapid tablet break-up for faster absorption.
- Hydroxypropyl cellulose: Functions as a binder to maintain tablet integrity.
- Magnesium stearate: A lubricant used during the tabletting process to prevent sticking.
Film Coating
The film coating serves to protect the tablet, improve swallowability, and provide product identification. It contains:
- Hypromellose (E464): The primary film-forming agent.
- Titanium dioxide (E171): A white pigment that gives the tablet its color and protects the active substance from light.
- Talc: Used as a glidant in the coating process.
- Iron oxide red (E172): A colorant used for tablet identification.
Edoxaban Zentiva 15 mg tablets are typically small, round, film-coated tablets. The specific appearance may vary by market; refer to the patient information leaflet included with your medication for exact description. For patients with known allergies to any of the excipients listed above, alternative anticoagulant therapy should be discussed with their prescribing physician.
Frequently Asked Questions About Edoxaban Zentiva
Medical References
This article is based on peer-reviewed clinical evidence and international medical guidelines. All medical claims are supported by Level 1A evidence where available.
- Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine. 2013;369(22):2093-2104. doi:10.1056/NEJMoa1310907 (ENGAGE AF-TIMI 48 trial)
- Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. New England Journal of Medicine. 2013;369(15):1406-1415. doi:10.1056/NEJMoa1306638
- European Medicines Agency (EMA). Edoxaban — Summary of Product Characteristics (SmPC). Last updated 2024. Available at: ema.europa.eu
- Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. European Heart Journal. 2021;42(5):373-498. doi:10.1093/eurheartj/ehaa612
- Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021;23(10):1612-1676. doi:10.1093/europace/euab065
- Konstantinides SV, Meyer G, Becattini C, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism. European Heart Journal. 2020;41(4):543-603.
- Connolly SJ, Crowther M, Eikelboom JW, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. New England Journal of Medicine. 2019;380(14):1326-1335.
- World Health Organization (WHO). WHO Model List of Essential Medicines — 23rd List. 2023. Geneva: WHO.
- British National Formulary (BNF). Edoxaban tosilate. National Institute for Health and Care Excellence (NICE). Last updated 2024.
About Our Medical Editorial Team
This article has been written and reviewed by iMedic's medical editorial team, consisting of licensed physicians with specialist training in cardiology, hematology, clinical pharmacology, and internal medicine.
📋 Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
🔎 Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
🔄 Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
✎ Corrections Policy
Any errors are corrected immediately with a transparent changelog.
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in cardiology, hematology, clinical pharmacology, and internal medicine.